共 352 条
[1]
Mantovani L(2016)Burden of moderate-to-severe plaque psoriasis and new therapeutic approaches (secukinumab): an Italian Perspective Dermatol Ther (Heidelb) 6 151-167
[2]
Medaglia M(2008)Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics J Am Acad Dermatol 58 851-864
[3]
Piacentini P(2008)Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 826-850
[4]
Gottlieb A(2007)The risk of mortality in patients with psoriasis: results from a population-based study Arch Dermatol 143 1493-1499
[5]
Korman NJ(2009)British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009 Br J Dermatol 161 987-1019
[6]
Gordon KB(2018)Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain Clinicoecon Outcomes Res 10 747-759
[7]
Menter A(2018)Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study Ann Rheum Dis 77 228-233
[8]
Gottlieb A(2013)FRI0162 Investigation into the binding affinity of certolizumab pegol to FcRn and functional consequences for FcRn-mediated transcytosis: comparison to infliximab, adalimumab and etanercept Ann Rheum Dis 72 A426-545
[9]
Feldman SR(2006)A new generation of high-affinity humanized PEGylated Fab´ fragment anti-tumor necrosis factor-alpha monoclonal antibodies Therapy 3 535-900
[10]
Gelfand JM(2005)Simultaneous comparison of multiple treatments: combining direct and indirect evidence BMJ 331 897-337